Why the study?
Does glimepiride improve glycemic control in patients with NIDDM previously treated with sulfonylureas?
Population
304 patients with NIDDM who have previously received sulfonylurea agents
Comparison
Glimepiride 1, 4, or 8 mg once daily for 14 weeks vs Placebo
Design
RCT, randomized
Follow-up
14 weeks
Authors
Loading...
Supports glimepiride for glycemic control in sulfonylurea-pretreated NIDDM; confirms dose-dependent efficacy in this RCT population.
Does glimepiride improve glycemic control in patients with NIDDM previously treated with sulfonylureas?
Glimepiride at doses of 1, 4, and 8 mg once daily provides significant, dose-dependent improvements in glycemic control in patients with NIDDM.
Goldberg et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: